{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:48:24Z","timestamp":1780508904433,"version":"3.54.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02282-w","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:59:54Z","timestamp":1744189194000},"page":"1469-1477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative validation of the Mayo Clinic\u00a0imaging classification and PROPKD score for predicting ADPKD progression across diverse ethnic cohorts"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-8047","authenticated-orcid":false,"given":"Yasar","family":"Caliskan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmecit","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hande","family":"Aypek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur A.","family":"Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuma B.","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alparslan","family":"Demiray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsah","family":"Cecener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigit","family":"Kurtulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Bastani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Kocyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"3","key":"2282_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audrezet MP, Rousseau A et al (2016) The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27(3):942\u2013951. https:\/\/doi.org\/10.1681\/ASN.2015010016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2282_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/ndt\/gfx188","volume":"33","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall E, Blais JD, Irazabal MV et al (2018) Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant 33(4):645\u2013652. https:\/\/doi.org\/10.1093\/ndt\/gfx188","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2282_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/nep.13640","volume":"25","author":"S Chan","year":"2020","unstructured":"Chan S, Patel C, Mallett AJ (2020) Pilot clinical and validation study of the PROPKD score in clinical practice amongst patients with Autosomal Dominant Polycystic Kidney Disease. Nephrology (Carlton) 25(3):274\u2013275. https:\/\/doi.org\/10.1111\/nep.13640","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"2282_CR4","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1093\/ndt\/gfaa283","volume":"36","author":"CJ Blijdorp","year":"2021","unstructured":"Blijdorp CJ, Severs D, Musterd-Bhaggoe UM et al (2021) Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 36(12):2248\u20132255. https:\/\/doi.org\/10.1093\/ndt\/gfaa283","journal-title":"Nephrol Dial Transplant"},{"key":"2282_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-02053-z","author":"N Ebrahimi","year":"2024","unstructured":"Ebrahimi N, Vakhshoori M, Chebib F et al (2024) Evaluating physician confidence and barriers in prescribing tolvaptan for ADPKD management: a comprehensive online survey study. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-024-02053-z","journal-title":"J Nephrol"},{"issue":"3","key":"2282_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10157-012-0706-3","volume":"17","author":"A Ozkok","year":"2013","unstructured":"Ozkok A, Akpinar TS, Tufan F et al (2013) Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol 17(3):345\u2013351. https:\/\/doi.org\/10.1007\/s10157-012-0706-3","journal-title":"Clin Exp Nephrol"},{"issue":"19","key":"2282_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"issue":"12","key":"2282_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010541","volume":"8","author":"BG Choi","year":"2019","unstructured":"Choi BG, Rha SW, Yoon SG, Choi CU, Lee MW, Kim SW (2019) Association of major adverse cardiac events up to 5 years in patients with chest pain without significant coronary artery disease in the korean population. J Am Heart Assoc 8(12):e010541. https:\/\/doi.org\/10.1161\/JAHA.118.010541","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2282_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000522226","volume":"53","author":"AJ Bleyer","year":"2022","unstructured":"Bleyer AJ, Westemeyer M, Xie J et al (2022) Genetic etiologies for chronic kidney disease revealed through next-generation renal gene panel. Am J Nephrol 53(4):297\u2013306. https:\/\/doi.org\/10.1159\/000522226","journal-title":"Am J Nephrol"},{"issue":"5","key":"2282_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"2282_CR11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2147\/TCRM.S196244","volume":"15","author":"A Rastogi","year":"2019","unstructured":"Rastogi A, Ameen KM, Al-Baghdadi M et al (2019) Autosomal dominant polycystic kidney disease: updated perspectives. Ther Clin Risk Manag 15:1041\u20131052. https:\/\/doi.org\/10.2147\/TCRM.S196244","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2282_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/ijn.ijn_69_22","volume":"33","author":"S Singh","year":"2023","unstructured":"Singh S, Sreenidhi HC, Das P, Devi C (2023) Predicting the risk of progression in Indian ADPKD cohort using PROPKD score - a single-center retrospective study. Indian J Nephrol May-Jun 33(3):195\u2013201. https:\/\/doi.org\/10.4103\/ijn.ijn_69_22","journal-title":"Indian J Nephrol May-Jun"},{"issue":"7","key":"2282_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2215\/CJN.00840122","volume":"17","author":"RL McGill","year":"2022","unstructured":"McGill RL, Saunders MR, Hayward AL, Chapman AB (2022) Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States. Clin J Am Soc Nephrol 17(7):976\u2013985. https:\/\/doi.org\/10.2215\/CJN.00840122","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5993","key":"2282_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese G, Friedman DJ, Ross MD et al (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329(5993):841\u2013845. https:\/\/doi.org\/10.1126\/science.1193032","journal-title":"Science"},{"issue":"2","key":"2282_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/j.ajkd.2019.03.414","volume":"74","author":"BI Freedman","year":"2019","unstructured":"Freedman BI, Spainhour M, Hicks PJ et al (2019) Nephropathy progression in african americans with a family history of ESKD: Implications for clinical trials in APOL1-associated nephropathy. Am J Kidney Dis 74(2):284\u2013286. https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.414","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2282_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU Muller","year":"2022","unstructured":"Muller RU, Messchendorp AL, Birn H et al (2022) An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant 37(5):825\u2013839. https:\/\/doi.org\/10.1093\/ndt\/gfab312","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2282_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40620-016-0349-7","volume":"29","author":"P Messa","year":"2016","unstructured":"Messa P, Alfieri CM, Montanari E, Ferraresso M, Cerutti R (2016) ADPKD: clinical issues before and after renal transplantation. J Nephrol 29(6):755\u2013763. https:\/\/doi.org\/10.1007\/s40620-016-0349-7","journal-title":"J Nephrol"},{"issue":"5","key":"2282_CR18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.06.017","volume":"66","author":"EM Spithoven","year":"2015","unstructured":"Spithoven EM, van Gastel MD, Messchendorp AL et al (2015) Estimation of total kidney volume in autosomal dominant polycystic kidney disease. Am J Kidney Dis 66(5):792\u2013801. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.017","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"2282_CR19","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa1205511","journal-title":"N Engl J Med"},{"issue":"24","key":"2282_CR20","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD et al (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2255\u20132266. https:\/\/doi.org\/10.1056\/NEJMoa1402685","journal-title":"N Engl J Med"},{"issue":"24","key":"2282_CR21","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","volume":"371","author":"VE Torres","year":"2014","unstructured":"Torres VE, Abebe KZ, Chapman AB et al (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2267\u20132276. https:\/\/doi.org\/10.1056\/NEJMoa1402686","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02282-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:03Z","timestamp":1777564743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/5\/1469\/8457152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02282-w","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Caliskan: None; A. Yildiz; None; H. Aypek: None; O.A. Oto: None; C.B. Gul: None, A. Demiray: None, G. Cecener: None; Y. Kurtulus: None; B. Bastani: None; I. Kocyigit: None; K.L. Lentine reports the following: Consultancy: CareDx, Inc.; and Speakers Bureau: Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by each institutional review board in agreement with the Declaration of Helsinki. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The SSM Health Saint Louis University study \"Clinical Outcomes of Patients with Inherited Kidney Diseases\" (IRB Protocol # 32839) has been approved by Saint Louis University IRB. A waiver of consent was granted for retrospective record review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients consented for genetic testing as part of their routine clinic evaluation, according to our clinical protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and consent to participate"}}]}}